{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:41:27Z","timestamp":1761061287199,"version":"build-2065373602"},"reference-count":60,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.bbmt.2017.11.012","type":"journal-article","created":{"date-parts":[[2017,12,5]],"date-time":"2017-12-05T22:36:32Z","timestamp":1512513392000},"page":"452-459","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Immune Reconstitution Following Autologous Stem Cell Transplantation in Patients with High-Risk Neuroblastoma at the Time of Immunotherapy"],"prefix":"10.1016","volume":"24","author":[{"given":"Michele L.","family":"Nassin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elitsa","family":"Perizes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeep","family":"Gurbuxani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5749-7650","authenticated-orcid":false,"given":"Susan L.","family":"Cohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John M.","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6776-4695","authenticated-orcid":false,"given":"James L.","family":"LaBelle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2011","series-title":"SEER Cancer Statistics Review, 1975-2008","key":"10.1016\/j.bbmt.2017.11.012_bib0010"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0015","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(07)60983-0","article-title":"Neuroblastoma","volume":"369","author":"Maris","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0020","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2008.16.6785","article-title":"The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report","volume":"27","author":"Cohn","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0025","doi-asserted-by":"crossref","first-page":"16078","DOI":"10.1038\/nrdp.2016.78","article-title":"Neuroblastoma","volume":"2","author":"Matthay","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0030","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1200\/JCO.2014.59.4648","article-title":"Advances in risk classification and treatment strategies for neuroblastoma","volume":"33","author":"Pinto","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0035","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1056\/NEJM199910143411601","article-title":"Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid","volume":"341","author":"Matthay","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0040","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1056\/NEJMoa0911123","article-title":"Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma","volume":"363","author":"Yu","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0045","first-page":"144","article-title":"Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells","volume":"51","author":"Barker","year":"1991","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0050","first-page":"362","article-title":"A mechanism for neutrophil-mediated lysis of human neuroblastoma cells","volume":"53","author":"Barker","year":"1993","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0055","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1053\/j.seminoncol.2015.05.012","article-title":"Enhancing cancer immunotherapy via activation of innate immunity","volume":"42","author":"Goldberg","year":"2015","journal-title":"Semin Oncol"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0060","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/BF00199217","article-title":"Granulocyte-monocyte-colony-stimulating factor augments the cytotoxic capacity of lymphocytes and monocytes in antibody-dependent cellular cytotoxicity","volume":"29","author":"Masucci","year":"1989","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0065","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/S0959-8049(97)00053-1","article-title":"Granulocyte-macrophage colony-stimulating factor improves immunological parameters in patients with refractory solid tumours receiving second-line chemotherapy: correlation with clinical responses","volume":"33","author":"Baxevanis","year":"1997","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0070","first-page":"5234","article-title":"Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2","volume":"50","author":"Hank","year":"1990","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0075","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.4049\/jimmunol.130.4.1970","article-title":"Interleukin 2 dependence of human natural killer (NK) cell activity","volume":"130","author":"Domzig","year":"1983","journal-title":"J Immunol"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0080","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/nrclinonc.2014.168","article-title":"Mechanisms of neuroblastoma regression","volume":"11","author":"Brodeur","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0085","first-page":"3","article-title":"Immunotherapy targets in pediatric cancer","volume":"2","author":"Orentas","year":"2012","journal-title":"Front Oncol"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0090","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/sj.bmt.1700626","article-title":"Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow","volume":"19","author":"Talmadge","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0095","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1182\/blood.V92.5.1471","article-title":"Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation","volume":"92","author":"Guillaume","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0100","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.beha.2006.09.009","article-title":"Immune reconstitution following hematopoietic stem-cell transplantation","volume":"20","author":"Geddes","year":"2007","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0105","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/sj.bmt.1703831","article-title":"Rapid immune reconstitution following autologous hematopoietic stem cell transplantation in children: a single institution experience","volume":"31","author":"Hoepfner","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0110","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.bbmt.2011.08.007","article-title":"Peripheral blood lymphocyte and monocyte recovery and survival in acute leukemia postmyeloablative allogeneic hematopoietic stem cell transplant","volume":"18","author":"Thoma","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0115","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.bbmt.2017.04.013","article-title":"Prognostic analysis of absolute lymphocyte and monocyte counts after autologous stem cell transplantation in children, adolescents, and young adults with refractory or relapsed Hodgkin lymphoma","volume":"23","author":"Galvez-Silva","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0120","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.bbmt.2015.01.019","article-title":"Absolute lymphocyte count recovery after allogeneic hematopoietic stem cell transplantation predicts clinical outcome","volume":"21","author":"Kim","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0125","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/sj.bmt.1704082","article-title":"Early lymphocyte recovery is an important determinant of outcome following allogeneic transplantation with CD34+ selected graft and limited T-cell addback","volume":"32","author":"Chakrabarti","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0130","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/j.1365-2141.2006.06232.x","article-title":"Absolute lymphocyte count predicts overall survival in follicular lymphomas","volume":"134","author":"Siddiqui","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0135","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/MPH.0000000000000717","article-title":"Early lymphocyte recovery and outcome in osteosarcoma","volume":"39","author":"Lee","year":"2017","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0140","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/sj.leu.2404032","article-title":"Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia","volume":"20","author":"Behl","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0145","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/MPH.0b013e31802d3e3e","article-title":"Early lymphocyte recovery as a prognostic indicator for high-risk Ewing sarcoma","volume":"29","author":"De Angulo","year":"2007","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0150","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/sj.bmt.1705373","article-title":"Early lymphocyte recovery predicts longer survival after autologous peripheral blood stem cell transplantation in multiple myeloma","volume":"37","author":"Kim","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0155","doi-asserted-by":"crossref","first-page":"6459","DOI":"10.1200\/JCO.2005.05.571","article-title":"Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group","volume":"23","author":"London","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0160","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1200\/JCO.2016.67.2774","article-title":"The beginning of the end of package deal therapy for patients with high-risk neuroblastoma?","volume":"34","author":"Barrett","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0165","first-page":"460","article-title":"Phenotypic changes associated with activation of CD45RA+ and CD45RO+ T cells","volume":"69","author":"Wallace","year":"1990","journal-title":"Immunology"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0170","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/sj.bmt.1704185","article-title":"Identification of non-na\u00efve CD4+CD45RA+ T cell subsets in adult allogeneic haematopoietic cell transplant recipients","volume":"32","author":"Fallen","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0175","doi-asserted-by":"crossref","first-page":"368","DOI":"10.3389\/fimmu.2015.00368","article-title":"NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy","volume":"6","author":"Wang","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0180","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1365-2567.2008.03027.x","article-title":"CD56(bright) natural killer (NK) cells: an important NK cell subset","volume":"126","author":"Poli","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0185","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S1471-4906(01)02060-9","article-title":"The biology of human natural killer-cell subsets","volume":"22","author":"Cooper","year":"2001","journal-title":"Trends Immunol"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0190","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1182\/blood-2009-12-234096","article-title":"Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update","volume":"115","author":"Seggewiss","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0195","first-page":"901","article-title":"Time-course of the recovery of cellular immune function after high-dose chemotherapy and peripheral blood progenitor cell transplantation for high-grade non-Hodgkin's lymphoma","volume":"15","author":"Scheid","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0200","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/sj.thj.6200018","article-title":"Phenotypic and functional analysis of the HLA-class I-specific inhibitory receptors of natural killer cells isolated from peripheral blood of patients undergoing bone marrow transplantation from matched unrelated donors","volume":"1","author":"Vitale","year":"2000","journal-title":"Hematol J"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0205","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.1182\/blood-2002-08-2568","article-title":"Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation","volume":"101","author":"Shilling","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0210","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1182\/blood.V79.12.3239.bloodjournal79123239","article-title":"CD16- CD56+ natural killer cells after bone marrow transplantation","volume":"79","author":"Jacobs","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0215","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1084\/jem.171.5.1509","article-title":"Functional consequences of interleukin 2 receptor expression on resting human lymphocytes: identification of a novel natural killer cell subset with high affinity receptors","volume":"171","author":"Caligiuri","year":"1990","journal-title":"J Exp Med"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0220","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/mt.2014.50","article-title":"Ultra-low dose interleukin-2 promotes immune-modulating function of regulatory T cells and natural killer cells in healthy volunteers","volume":"22","author":"Ito","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0225","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1006\/meth.1996.0038","article-title":"Natural killer cell subsets and development","volume":"9","author":"Carson","year":"1996","journal-title":"Methods"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0230","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.bbmt.2008.12.426","article-title":"Immune reconstitution of regulatory T-cells following autologous hematopoietic stem cell transplantation","volume":"15","author":"Perez-Garcia","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0235","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.immuni.2005.01.016","article-title":"Regulatory T cell lineage specification by the forkhead transcription factor foxp3","volume":"22","author":"Fontenot","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0240","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nri2343","article-title":"How regulatory T cells work","volume":"8","author":"Vignali","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0245","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/j.cca.2011.11.006","article-title":"Surface markers of lymphocyte activation and markers of cell proliferation","volume":"413","author":"Shipkova","year":"2012","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0250","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.clim.2008.11.010","article-title":"CD4(+)CD25(+)CD127(low\/-) regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression","volume":"131","author":"Shen","year":"2009","journal-title":"Clin Immunol"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0255","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1007\/s00432-010-0816-9","article-title":"Higher intratumoral infiltrated Foxp3+ Treg numbers and Foxp3+\/CD8+ ratio are associated with adverse prognosis in resectable gastric cancer","volume":"136","author":"Shen","year":"2010","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0260","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1158\/1078-0432.CCR-06-2363","article-title":"FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis","volume":"13","author":"Kobayashi","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0265","doi-asserted-by":"crossref","first-page":"15179","DOI":"10.1038\/srep15179","article-title":"Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis","volume":"5","author":"Shang","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0270","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.1182\/blood-2008-11-190827","article-title":"Depletion of CD4 T cells enhances immunotherapy for neuroblastoma after syngeneic HSCT but compromises development of antitumor immune memory","volume":"113","author":"Jing","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0275","doi-asserted-by":"crossref","first-page":"6952","DOI":"10.1182\/blood-2010-12-326108","article-title":"Depletion of CD25(+) T cells from hematopoietic stem cell grafts increases posttransplantation vaccine-induced immunity to neuroblastoma","volume":"117","author":"Jing","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0280","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/01.cji.0000211336.91513.dd","article-title":"CD25+ regulatory T cell inhibition enhances vaccine-induced immunity to neuroblastoma","volume":"30","author":"Johnson","year":"2007","journal-title":"J Immunother"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0285","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S1470-2045(17)30070-0","article-title":"Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1\/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial","volume":"18","author":"Ladenstein","year":"2017","journal-title":"Lancet Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.bbmt.2017.11.012_bib0290","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/j.nucmedbio.2008.05.002","article-title":"Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma","volume":"35","author":"DuBois","year":"2008","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0295","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/sj.bmt.1702846","article-title":"Megatherapy combining I(131) metaiodobenzylguanidine and high-dose chemotherapy with haematopoietic progenitor cell rescue for neuroblastoma","volume":"27","author":"Miano","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0300","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.bbmt.2014.11.674","article-title":"Impact of serotherapy on immune reconstitution and survival outcomes after stem cell transplantations in children: thymoglobulin versus alemtuzumab","volume":"21","author":"Willemsen","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.11.012_bib0305","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1182\/blood-2016-06-724005","article-title":"Strategies before, during, and after hematopoietic cell transplantation to improve T-cell immune reconstitution","volume":"128","author":"de Koning","year":"2016","journal-title":"Blood"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879117308480?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879117308480?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:01:20Z","timestamp":1761058880000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879117308480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S1083879117308480"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2017.11.012","relation":{},"ISSN":["1083-8791"],"issn-type":[{"type":"print","value":"1083-8791"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune Reconstitution Following Autologous Stem Cell Transplantation in Patients with High-Risk Neuroblastoma at the Time of Immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2017.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}